Patents Assigned to VIRACTA SUBSIDIARY, INC.
  • METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS
    Publication number: 20240390375
    Abstract: Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.
    Type: Application
    Filed: August 6, 2024
    Publication date: November 28, 2024
    Applicants: VIRACTA SUBSIDIARY, INC., TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Ronald J. Berenson, Douglas V. Faller
  • Methods and compositions for treating viral or virally-induced conditions
    Patent number: 12083119
    Abstract: Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.
    Type: Grant
    Filed: December 8, 2021
    Date of Patent: September 10, 2024
    Assignees: VIRACTA SUBSIDIARY, INC., TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Ronald J. Berenson, Douglas V. Faller
  • HDAC inhibitor solid state forms
    Patent number: 11780822
    Abstract: The present disclosure relates to various solid-state forms of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide and methods of making the same. Such forms of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide are useful in preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders and inflammation.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: October 10, 2023
    Assignee: VIRACTA SUBSIDIARY, INC.
    Inventors: Xiaohu Deng, Stewart Jones, David Slack
  • HDAC inhibitor solid state forms
    Patent number: 11760748
    Abstract: The present disclosure relates to the crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide and methods of making the same. The crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide is useful in preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders and inflammation.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: September 19, 2023
    Assignee: VIRACTA SUBSIDIARY, INC.
    Inventors: Xiaohu Deng, Wanping Mai, Robert Mcrae, Biljana Nadjsombati